AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
niclosamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| nicotinic acid or nicotinoyl alcohol derivatives | 1912 | 50-65-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). Although suggested as a potential treatment for COVID-19 based on its broad antiviral activity, including in vitro activity against coronaviruses, there are no data to support the use of niclosamide in the treatment of COVID-19.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 87.34 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.774 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.724 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 30.130 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 53.951 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.070 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.240 | % | High | 1 |
| herg | hERG pIC50 | 4.527 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 194.089 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 38.371 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.250 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK2,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PIM3,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 74 | |||
| kinase-selectivity-class | AXL,DYRK1B,GRK2,MAPK7,PDK4,STK33,TEK,TTK | 8 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.533 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.228 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 159.588 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.200 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.407 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.230 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.521 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 225.424 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 5.700 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.150 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 4.335 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | BAYER PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P02DA01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTICESTODALS Salicylic acid derivatives |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000923 | Anticestodal Agents |
| MeSH PA | D000969 | Antinematodal Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000980 | Antiplatyhelmintic Agents |
| MeSH PA | D008975 | Molluscacides |
| MeSH PA | D010575 | Pesticides |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33904 | molluscicide |
| CHEBI has role | CHEBI:35442 | antiparasitic agent |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:87183 | STAT3 inhibitor |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
| CHEBI has role | CHEBI:167183 | piscicide |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Taenia Infection | indication | ||
| Diphyllobothrium Infections | indication | ||
| Hymenolepiasis Infections | indication | ||
| Dipylidiasis Infections | off-label use |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.39 | acidic |
| pKa2 | 8.6 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Anoctamin-1 | Ion channel | IC50 | 7.55 | CHEMBL | |||||
| Potassium channel subfamily T member 1 | Ion channel | ACTIVATOR | EC50 | 5.54 | IUPHAR | ||||
| Cytochrome P450 2C9 | Enzyme | EC50 | 7.05 | WOMBAT-PK | |||||
| Mast/stem cell growth factor receptor Kit | Kinase | IC50 | 4.56 | CHEMBL | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 4.98 | CHEMBL | |||||
| Proto-oncogene tyrosine-protein kinase Src | Kinase | IC50 | 5 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 2 | Kinase | IC50 | 4.64 | CHEMBL | |||||
| Tyrosine-protein kinase JAK2 | Kinase | IC50 | 5 | CHEMBL | |||||
| Angiopoietin-1 receptor | Kinase | IC50 | 4.17 | CHEMBL | |||||
| Tyrosine-protein kinase Lyn | Kinase | IC50 | 4.62 | CHEMBL | |||||
| Fibroblast growth factor receptor 1 | Kinase | IC50 | 4.88 | CHEMBL | |||||
| Aurora kinase A | Kinase | IC50 | 4.27 | CHEMBL | |||||
| RAC-alpha serine/threonine-protein kinase | Kinase | IC50 | 4.23 | CHEMBL | |||||
| Glycogen synthase kinase-3 beta | Kinase | IC50 | 4.11 | CHEMBL | |||||
| 3-phosphoinositide-dependent protein kinase 1 | Kinase | IC50 | 4.08 | CHEMBL | |||||
| Signal transducer and activator of transcription 3 | Transcription factor | IC50 | 6.60 | CHEMBL | |||||
| Replicase polyprotein 1ab | Enzyme | IC50 | 4.40 | CHEMBL | |||||
| Replicase polyprotein 1ab | Enzyme | IC50 | 6.55 | CHEMBL | |||||
| Replicase polyprotein 1a | Enzyme | IC50 | 4.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018264 | VUID |
| N0000146594 | NUI |
| D00436 | KEGG_DRUG |
| 4018264 | VANDF |
| C0028017 | UMLSCUI |
| CHEBI:7553 | CHEBI |
| VUT | PDB_CHEM_ID |
| CHEMBL1448 | ChEMBL_ID |
| DB06803 | DRUGBANK_ID |
| D009534 | MESH_DESCRIPTOR_UI |
| 4477 | PUBCHEM_CID |
| 8494 | IUPHAR_LIGAND_ID |
| 1532 | INN_ID |
| 8KK8CQ2K8G | UNII |
| 227721 | RXNORM |
| 4944 | MMSL |
| 5172 | MMSL |
| d01126 | MMSL |
| 002990 | NDDF |
| 387334008 | SNOMEDCT_US |
| 5975000 | SNOMEDCT_US |
| 8KK8CQ2K8G | INXIGHT DRUGS |
Pharmaceutical products:
None